Medical Economics March 22, 2024
CMS issues guidance and won’t pay for the drug for weight loss exclusively.
Medicare Part D will pay for the antiobesity drug Wegovy (semaglutide) when prescribed to cut risks of heart disease.
The U.S. Centers for Medicare & Medicaid Services this week issued guidance that current Medicare Part D and Medicaid coverage rules apply to the drug making headlines for its health effects including weight loss.
Reports about the change in Medicare policy surfaced this week starting in the Wall Street Journal.
The Medicare Part D coverage process
Glucagon-like peptide-1 receptor agonist drugs (GLP-1 RAs) have gained attention of physicians and the public.
Since its beginning in 2006, Medicare Part D has excluded from basic coverage all drugs when used...
Today's Sponsors
Today's Sponsor